Cabaletta Bio

Cabaletta Bio is a Philadelphia-based biotechnology company that specializes in the development of therapies for autoimmune diseases using engineered T-cell therapies. It was founded in 2017 with the stated mission of developing and launching curative targeted cellular therapies for people suffering from autoimmune diseases.

The company has collaborators in research from institutions such as the University of Pennsylvania and the Children's Hospital of Philadelphia as well as partnerships with other biotechnology companies, such as IASO Bio.

Cabaletta Bio has developed a platform that has two different strategies to address autoimmune diseases. The platform is known as CABA, which is an acronym for Cabaletta Approach to B cell Ablation. It identifies B cell-mediated autoimmune diseases and has two methods to address them: CARTA and CAART.

CARTA is an acronym for Chimeric Antigen Receptor T cell for Autoimmunity and this method is designed to reset the immune system by depleting transient B cells and replacing them with healthy B cells. Various candidates for this method are being developed to treat severe autoimmune diseases.

CAART is an acronym for Chimeric AutoAntibody Receptor T and several product candidates have been developed using this method. Each candidate is designed to treat specific autoimmune diseases such as mucosal pemphigus vulgaris.

Cabaletta Bio is a biotechnology company developing cellular therapies for autoimmune diseases that is headquartered in Randor Township, Pennsylvania and was founded in 2017 by Aimee Payne, Michael Milone, and Steven Nichtberger.

What if autoimmune diseases could be cured with a one-time treatment? At Cabaletta Bio, we believe it is possible.

Cabaletta Bio is a Philadelphia-based biotechnology company that specializes in the development of therapies for autoimmune diseases using engineered T-cell therapies. It was founded in 2017 with the stated mission of developing and launching curative targeted cellular therapies for people suffering from autoimmune diseases.

The company has collaborators in research from institutions such as the University of Pennsylvania and the Children's Hospital of Philadelphia as well as partnerships with other biotechnology companies, such as IASO Bio.

Cabaletta Bio has developed a platform that has two different strategies to address autoimmune diseases. The platform is known as CABA, which is an acronym for Cabaletta Approach to B cell Ablation. It identifies B cell-mediated autoimmune diseases and has two methods to address them: CARTA and CAART.

CARTA is an acronym for Chimeric Antigen Receptor T cell for Autoimmunity and this method is designed to reset the immune system by depleting transient B cells and replacing them with healthy B cells. Various candidates for this method are being developed to treat severe autoimmune diseases.

CAART is an acronym for Chimeric AutoAntibody Receptor T and several product candidates have been developed using this method. Each candidate is designed to treat specific autoimmune diseases such as mucosal pemphigus vulgaris.

Cabaletta Bio is a biotechnology company developing cellular therapies for autoimmune diseases that is headquartered in Randor Township, Pennsylvania and was founded in 2017 by Aimee Payne, Michael Milone, and Steven Nichtberger.

What if autoimmune diseases could be cured with a one-time treatment? At Cabaletta Bio, we believe it is possible.

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABA™) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABA™ platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ trial, which is a Phase 1 study for the treatment of patients with mucosal pemphigus vulgaris (mPV). We have advanced several other high-priority targets into discovery and preclinical testing, including five announced and two unannounced programs.

Our Mission

To harness the immune system through innovative cell and gene therapies to deliver accessible cures for patients.

Our Vision